Master One Thing - Rapamycin Longevity Series cover image

Brian Kennedy on Rapamycin Master Series | Aging is the biggest risk factor for age-related diseases

Master One Thing - Rapamycin Longevity Series

CHAPTER

Exploring Rapamycin Derivatives and Other Ways to Inhibit mtorc

Exploring the development of rapologues that target mTORC1 with greater specificity, minimizing side effects and maximizing benefits. Also discussing the potential of these derivatives in treating tuberous sclerosis and other related conditions.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner